Cagrilintide vs semaglutide (Wegovy/Ozempic) Mechanism: Cagrilintide: Amylin receptor agonist Semaglutide: GLP-1 receptor agonist Different pathways Weight loss: Cagrilintide alone: 10-12% Semaglutide alone: 10-15% Similar efficacy monotherapy Gastric emptying: Cagrilintide: Very strong delay Semaglutide: Moderate delay Cagrilintide more powerful Side effects: Cagrilintide: More GI effects (stronger gastric slowing) Semaglutide: Moderate GI effects Cagrilintide harder to tolerate for some Availability: Cagrilintide: Investigational (not approved) Semaglutide: FDA approved, widely available Semaglutide easier to obtain currently Combination potential: Synergistic together (CagriSema) 15-25% weight loss combined Best of both mechanisms Verdict: Similar monotherapy efficacy, but combine for maximum results

Health Risks: Using an expired injectable medication could lead to adverse reactions, such as irritation at the injection site, infections, or even systemic side effects if the medication is compromised
Eat bland or easy-to-digest foods
Most GLP-1 providers in Miami prescribe GLP-1 (Ozempic) through a telehealth questionnaire, mail the medication, and move on
Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus
The court is including these cases in the broader semaglutide multidistrict litigation, where plaintiffs seek compensation for medical expenses, lost wages, and lasting health issues